Overview of Avitron-V

Property	Description
Active ingredient	Thiamine Hydrochloride (Vitamin B1)
Form	Tablet, Capsule, Injectable Solution
Pharmacological class	Vitamins and Minerals Supplement (Water-Soluble B Vitamin)
Common use	Nutritional Supplementation; Prevention of Thiamine Deficiency
Origin	Primarily Synthetic

What is Avitron-V and What Type of Supplement is It?

Avitron-V is a classified pharmaceutical preparation that functions as an essential nutritional supplement, belonging to the Vitamins and Minerals Supplement category. The active entity is Thiamine Hydrochloride, which is the stable salt of Thiamine, known universally as Vitamin B1 or Aneurine. Thiamine is classified as an essential medicine for addressing deficiency states, reflecting the compound’s foundational importance in global health. This substance is classified as a water-soluble B vitamin, which dictates that it is not stored extensively in the body and must be regularly supplied.

What is Avitron-V Made Of: Composition and Origin

The composition of Avitron-V is centered on the single ingredient Thiamine Hydrochloride, defining it as a monocomponent product derived primarily through a synthetic manufacturing process to ensure stability and purity. The final preparations are provided in several dosage forms, most frequently as oral solid forms, such as a tablet or capsule. It is also offered as a sterile injectable solution for parenteral administration, which provides an alternative route when guaranteed systemic delivery is required.

What is the General Purpose of Taking Avitron-V?

The overarching purpose of Avitron-V is to sustain vital metabolic functions by providing the necessary precursor for the active coenzyme form, thiamine pyrophosphate (TPP). This compound is an indispensable cofactor for the processes involved in cellular energy generation. Thiamine is recognized for its critical role in glucose metabolism and energy production. It is essential for the function of converting food into the energy needed by the nervous system and muscles. By supplying this essential nutrient, the medicine is utilized for nutritional supplementation and the correction of Thiamine deficiency.

What side effects are possible with Avitron-V?

Possible Side Effects and Safety Information

The official safety profile for Avitron-V (Thiamine Hydrochloride) is structured primarily around the risk of hypersensitivity reactions, particularly when administered via the injectable (parenteral) route. This information is derived from government regulatory documents, focusing on documented adverse events and established limitations.

Documented Adverse Reactions and Frequencies

Adverse reactions are officially grouped into system-organ classes. The most common manifestations listed include dermatological reactions such as pruritus (itching), rash, urticaria (hives), and a general feeling of warmth or sweating. Local effects at the injection site, such as tenderness and induration, may also occur.

Serious adverse reactions are classified as Rare in official documents, but they include the potential for life-threatening systemic responses. These may involve anaphylaxis, pulmonary edema, and collapse.

Regulatory Safety Considerations

The most severe events, including anaphylaxis, have been specifically associated with repeated administration of the injectable solution, according to regulatory data. The safety profile also includes constraints related to specific populations and prior sensitivities.

Safety Constraint	Scope and Context
Official Contraindication	A prior history of sensitivity to thiamine or to any of the product’s components restricts use.
Population-Specific Note	The injectable formulation contains aluminum and carries a risk of toxicity with prolonged parenteral administration in patients with impaired kidney function and premature neonates.

This regulatory framework establishes the Immune System as the primary safety domain of concern and dictates necessary safety limitations based on patient condition and administration route.

Overdose and Emergency Response

Avitron-V Overdose and When to Seek Help

The official regulatory documentation for Avitron-V (Thiamine Hydrochloride) indicates that toxicity following oral administration is uncommon, as the water-soluble nature of the compound allows excess amounts to be rapidly excreted from the body. Consequently, regulatory prescribing information does not list a defined symptom profile for overdose by this route.

The primary acute risk documented relates to serious hypersensitivity or anaphylactic reactions reported following parenteral administration (injection), especially after repeated doses. Such severe acute reactions may manifest with symptoms like a feeling of warmth, pruritus (itching), weakness, or tightness of the throat. Life-threatening outcomes, including cardiovascular collapse, pulmonary edema, and cyanosis, have also been reported.

In the event of accidental overdose, regulatory guidance mandates that a doctor or poison control center be contacted immediately. For any severe manifestations, such as trouble breathing, passing out, or collapse, the instruction is to contact emergency services without delay. No specific antidote is described in the official labeling; treatment involves symptomatic and supportive measures, including maintaining a patent airway and the use of epinephrine and oxygen to manage the acute reaction.

Therapeutic Uses of Avitron-V

Avitron-V (Thiamine Hydrochloride) is a therapeutic product primarily used for the correction of Thiamine (Vitamin B1) deficiency and supports the patient in managing the critical health consequences that arise from this deficit. Its use is considered relevant in clinical settings where a prolonged lack of this essential nutrient disrupts the body's major, energy-dependent systems, particularly the nervous system and the heart.

The medication is commonly used to help with established, severe deficiency conditions, including Beriberi (wet and dry forms) and the acute neurological state known as Wernicke’s encephalopathy. These indications address symptoms related to increased neurological or muscular activity and systemic imbalance. It is used for managing symptom clusters that may become intense or disruptive, such as profound mental confusion, uncoordinated gait (ataxia), and peripheral neuropathy (tingling, numbness).

It is relevant for easing systemic and cardiovascular signs, including edema (swelling) and rapid heart rate linked to deficiency-induced heart failure. This supportive use contributes to improved day-to-day comfort during symptomatic periods and may assist with addressing potentially disabling neurological manifestations.

Quick Facts: Therapeutic Applications

Is relevant for easing symptoms linked to deficiency-induced heart failure.
Is used for managing symptom clusters that include mental confusion and unsteady gait.
Supports patients during episodes of severe nutritional deficit.

Regulatory References

NIH MedlinePlus overview on Thiamine

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Avitron-V

The eligibility profile for Avitron-V (Thiamine Hydrochloride) is based on patient-specific criteria and conditional use categories outlined in governmental regulatory documents.

Absolute Contraindication

Avitron-V is strictly contraindicated in patients with a known hypersensitivity or allergy to thiamine (Vitamin B1) or to any other inactive ingredient contained within the formulation. This is the only absolute exclusion defined in official labeling.

Age-Group Eligibility

The medicine is generally permitted for Adults and Older Adults. For oral tablet or capsule forms, use is not recommended for children under three years of age. However, the injectable form is specifically indicated for infants and critically ill children for the treatment of acute deficiency conditions like infantile beriberi.

Conditional Use and Restrictions

Use is conditional during pregnancy and lactation, where administration should only occur if the medical need is clearly needed or after exercising caution. Patients with impaired kidney function require monitoring when receiving the injectable formulation over prolonged periods due to warnings related to aluminum accumulation. Furthermore, conditions such as severe vomiting or malabsorption define eligibility for the parenteral route over the oral form.

What should I know about interactions with other medicines?

Avitron-V Interactions with other medicines and products

This section describes the interactions for Avitron-V (Thiamine Hydrochloride) that are officially documented in government regulatory sources. This information is non-advisory and focuses only on established interaction patterns.

Documented Interacting Substances

Interaction Type	Interacting Medicines or Products
Antagonism (Neutralization)	Fluoropyrimidines (e.g., 5-Fluorouracil, Capecitabine); Thiosemicarbazone
Altered Clearance	Loop Diuretics (e.g., Furosemide)
Physical Incompatibility	Alkaline Solutions (e.g., Sodium Bicarbonate); specific Antibiotics (e.g., Ampicillin)

Official Interaction Statements

Certain cytotoxic medicines, specifically fluoropyrimidines, are officially documented to act as Thiamine antagonists, which effectively neutralizes the effect of Avitron-V. This is an anti-vitamin action noted in regulatory prescribing information.

Separately, Loop Diuretics are stated in official documents to cause an increase in the urinary excretion of Thiamine. This effect may result in reduced systemic levels of the vitamin.

For the injectable solution only, physical incompatibility is documented with alkaline solutions and certain antibiotics. This constraint requires separation when compounding or co-administering the medicines. Furthermore, high doses of Avitron-V are known to cause false positive results in the urobilinogen determination lab test.

Mechanism of Action

The mechanism of action for Avitron-V (Thiamine) begins with its metabolic conversion into the active coenzyme, Thiamine Pyrophosphate (TPP). TPP acts as a mandatory cofactor that binds to and activates critical mitochondrial enzymes: Pyruvate Dehydrogenase (PDH) and **alpha-Ketoglutarate Dehydrogenase (alpha-KGDH. This activity addresses a stoichiometric deficit in key energy pathways, restoring the efficiency of carbohydrate breakdown and subsequent cellular mathbfATP generation.

This modulation of the energy deficit state significantly affects tissues with high, continuous metabolic demands, specifically the Central Nervous System (CNS) and the heart muscle. By sustaining PDH and alpha-KGDH activity, the mechanism supports consistent mathbfATP generation, which maintains neuronal membrane potentials and influences the constant energy supply required for nerve conduction and cardiac contractility.

Beyond core energy production, TPP is necessary for Transketolase in the Pentose Phosphate Pathway, which is a parallel process generating essential precursors for nucleotides and certain neurotransmitters. The mechanism also facilitates the clearance of metabolic byproducts like pyruvate and lactate by allowing them to enter the TCA cycle, influencing processes necessary for neuronal integrity and chemical communication.

Dosage and Administration Information

How Avitron-V (Thiamine Hydrochloride) is Used

Avitron-V is utilized according to highly structured protocols that depend on the severity of the deficiency. Administration occurs through oral forms, such as tablets or capsules, or via parenteral injection (intramuscular or intravenous).

Administration Routes and Dosing Patterns

The choice of route and the intensity of the dose are dictated by clinical need. Low-dose regimens, such as 1.1 mg to 1.2 mg daily, align with nutritional requirements for prophylaxis or long-term maintenance. For correcting established deficiency, oral dosing is typically higher, such as 5 mg to 10 mg three times daily.

Parenteral administration is reserved for acute situations requiring rapid systemic restoration. For conditions like Wernicke's encephalopathy, intensive regimens may begin with a single high dose of 100 mg intravenously, transitioning to 50 mg to 100 mg intramuscularly daily until the patient can tolerate oral intake.

Procedural and Time-Relationship Concepts

Usage Concept	Official Protocol Summary
Frequency	Ranges from once daily (maintenance) to multiple times daily (acute treatment).
Duration	Used in a short-term parenteral course (e.g., up to two weeks) followed by long-term oral maintenance.
Timing & Preparation	Oral forms can be taken with or without food. IV administration must be performed slowly as an infusion over a specific time, such as 30 minutes, and the Thiamine should be administered prior to intravenous dextrose solutions.
Population Use	Dosing guidelines are available for pediatric patients, but no mandatory dose adjustment is specified for older adults or patients with renal or hepatic impairment.

The structured use of Avitron-V defines a clear progression from rapid parenteral intervention to sustained oral therapy, ensuring consistency in administration protocols.

Recent Clinical Evidence

Avitron-V: Recent Clinical Evidence

Evidence for Use in Severe Deficiency Conditions (Wernicke’s Encephalopathy and Beriberi)

Avitron-V (Thiamine) was studied in research examining severe nutritional deficits, including Wernicke’s Encephalopathy and the various forms of Beriberi. The evidence base includes established observational studies and regulatory reviews, alongside Randomized Controlled Trials (RCTs). Researchers examined outcomes related to neurological function (such as confusion and coordination) and physiological strain over defined short-term intervals. Findings describe patterns of change in acute symptoms during the study period. Uncertainty remains regarding the optimal dosage regimen for managing acute deficiency, as RCTs comparing regimens have provided mixed findings.

Research for Supportive Use in High-Risk Populations

Research has explored the use of Avitron-V in patient groups at higher risk of developing a deficiency, such as those with chronic alcohol use disorder, Type 2 Diabetes Mellitus, and Congestive Heart Failure. Systematic reviews and smaller intervention trials examined outcomes related to shifts in thiamine biomarker levels and metabolic markers. However, when research examined specific long-term outcomes in non-deficient individuals, the findings were often mixed or limited and heterogeneous across different study groups.

Key Research Gaps and Limitations

Specific research has also examined use in high-vulnerability groups, including infantile populations and patients with specific comorbid conditions. For many of these specialized groups, the data for certain groups remain insufficient, and certainty remains low regarding the generalized outcomes. Follow-up durations are often short-term, meaning data related to long-term outcomes and the durability of patient responses are not fully established. Comparative evidence is also often lacking for evaluating Avitron-V relative to specific supportive measures.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Avitron-V (FAQ)

Q: How quickly should I start feeling the effects of Avitron-V?

A: Studies on Thiamine (Avitron-V) show that it is rapidly absorbed, particularly following parenteral (injectable) administration. Rapid systemic restoration is a primary goal of parenteral administration, and initial clinical changes may be observed within 24 to 48 hours in severe deficiency cases.

Q: Is it normal to have mild stomach upset after starting Avitron-V?

A: Official patient information notes that mild gastrointestinal symptoms, such as nausea or stomach discomfort, may be experienced. This is noted as a possible side effect of Thiamine use.

Q: Can people with kidney problems safely use Avitron-V?

A: Warnings exist regarding the injectable form when used long-term in patients with impaired kidney function, which may require clinical review due to the risk of aluminum accumulation. No mandatory dose adjustment is usually specified for the oral form in patients with kidney impairment.

Q: Can Avitron-V interact with herbal supplements?

A: The official product information primarily lists interactions with specific prescription and over-the-counter medications. While no specific herbal supplements are listed as documented interactions, patients are generally advised by regulatory documents to discuss all supplements with a healthcare professional.

Q: What are the serious side effects of Avitron-V that I need to look out for?

A: Official warnings note that rare, serious adverse reactions can occur, most notably severe hypersensitivity or anaphylaxis. Signs associated with these serious reactions include difficulty breathing or swelling of the face. If these occur, patients should seek immediate clinical evaluation.

Q: Does alcohol consumption interfere with Avitron-V's effectiveness?

A: Chronic alcohol use disorder is widely recognized as a major cause of Thiamine deficiency. Alcohol can compromise both the body's absorption and storage of the vitamin, impacting its intended effect and availability.

Q: Does Avitron-V have any known interactions with birth control pills?

A: The established drug interaction list for Avitron-V details specific drug classes that interfere with its action. Birth control pills are not listed as a known, documented interaction in the official product labeling.

Q: Is a slight dizziness a sign of a serious side effect from Avitron-V?

A: Dizziness is not explicitly listed as a common side effect in official documents. However, rare systemic reactions can involve low blood pressure, and patients experiencing sudden or severe dizziness should consider seeking clinical review, as it may be related to systemic changes.

Q: How does Avitron-V affect liver function?

A: The liver is one of the primary organs responsible for converting Thiamine into its active coenzyme form. Despite this role, official guidelines do not typically specify a mandatory dose adjustment for patients with pre-existing hepatic (liver) impairment.

Q: What are the potential withdrawal symptoms if I stop Avitron-V suddenly?

A: There is no mention of withdrawal or rebound effects in the official regulatory labels for this vitamin supplement, which is generally not associated with dependency.

Q: Is Avitron-V a controlled substance?

A: No, Thiamine (Vitamin B1), the active ingredient in Avitron-V, is not classified as a controlled substance under the US Controlled Substances Act.

Q: What happens if you take too much Avitron-V?

A: Thiamine is a water-soluble vitamin, and excess amounts are typically excreted. If there is concern about an overdose, official guidance recommends seeking clinical review or contacting a poison control center.

Q: Is there a generic version of Avitron-V available?

A: Yes, the active ingredient, Thiamine Hydrochloride, is a long-established substance that is widely available in generic forms and as an over-the-counter vitamin supplement.

Q: How long does Avitron-V stay in your system after stopping treatment?

A: As a water-soluble B vitamin, Avitron-V is not stored in large quantities in the body. Excess amounts are rapidly processed and excreted in the urine, giving it a relatively short duration of action in the system.

Q: What are the common signs that Avitron-V is actually working?

A: When used to correct a deficiency, the effectiveness of Avitron-V is measured by the prevention or reversal of deficiency-related symptoms. This includes reported improvements in neurological function, reduced confusion, and the correction of related metabolic imbalances.

Q: What are the main benefits of using Avitron-V instead of just lifestyle changes?

A: Avitron-V is specifically indicated to treat or prevent Thiamine deficiency syndromes in cases where dietary changes alone are insufficient. For severe, acute conditions, medical administration of the vitamin is a necessary, targeted intervention.

Q: Is Avitron-V used for preventative health, or only for active conditions?

A: Avitron-V is indicated for both purposes. It is used for nutritional supplementation to prevent deficiency, and it is also indicated for the active treatment of established, severe deficiency syndromes like beriberi.

Q: Can Avitron-V make existing medical conditions worse?

A: Avitron-V is strictly contraindicated only in patients with a known hypersensitivity to thiamine. In rare contexts, such as rapid administration of high doses to patients with severe beriberi, there have been warnings associated with acute pulmonary edema.

Q: Can Avitron-V be taken at the same time as my thyroid medication?

A: The official documentation lists specific drug types that interact with Avitron-V. Thyroid medications are not listed as a known, documented interaction in the official product labeling.

Q: Is Avitron-V considered a 'new' drug, or has it been around for a while?

A: Thiamine (Vitamin B1) is a very well-established substance. It was first isolated in the 1920s and synthesized in the 1930s, meaning it has a long history of medical use.

Q: Is it okay to crush or chew Avitron-V tablets?

A: Tablets should generally be swallowed whole with water, as intended by the manufacturer, unless otherwise specified for specific scored tablets.

Q: Does Avitron-V affect blood pressure readings?

A: Hypotension (low blood pressure) is listed as a rare, serious adverse effect that can occur after rapid intravenous injection. Additionally, since Thiamine deficiency can affect the heart, correcting the deficiency may influence cardiovascular function.

Q: What is the half-life of Avitron-V?

A: The specific half-life (the time it takes for half the drug to be eliminated) is not always consistently published in official labels for this vitamin. However, since it is a water-soluble vitamin that is rapidly processed and excreted in the urine, its duration of action in the body is relatively short.

How should Avitron-V be stored and disposed of?

Official Storage and Disposal Requirements

Requirement Area	Regulatory Statement
Temperature & Protection	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Protect from moisture and excessive heat. Do not freeze.
Packaging Rules	Keep the medicine in the original container and keep the container tightly closed. Protect from light by storing in the outer carton.
In-Use Stability	If applicable, discard any unused portion 28 days after first opening or reconstitution.
Safety & Disposal	Keep Avitron-V out of the sight and reach of children. Dispose of expired or unused product through an authorized drug take-back program. If a take-back option is unavailable, follow official guidelines for mixing with an undesirable substance before disposal in household trash. Do not pour down a drain or flush unless specifically authorized.

These official statements define the required conditions for maintaining product stability and safety. The product's integrity is protected by keeping it within the mandatory temperature range and sealed in the original packaging, while disposal guidelines ensure proper environmental handling of unused medication.

Avitron-V